New imaging agent could sharpen detection of blood cancers
NCT ID NCT02128945
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells. If it works, it could offer a more accurate way to image these cancers than the current standard tracer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital
Caen, 14000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]-Fludarabine (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a more accurate PET scan for detecting and monitoring certain blood cancers, especially chronic lymphocytic leukemia.
What could go wrong
This is a very early, small study (10 people) focused on safety and imaging, not treatment. The new tracer may not prove better than the current standard scan.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.